FGF23 and X-linked hypophosphatemia: Recently, burosumab, a human monoclonal antibody against FGF23, has been approved for the therapy of X-linked hypophosphatemia in children and adults, the most common heritable, genetically-determined form of FGF23-related hypophosphatemic disease [19].